Antares Pharma, Inc. (NASDAQ:ATRS) went up by 2.53% from its latest closing price when compared to the 1-year high value of $3.96 and move down -22.22%, while ATRS stocks collected -1.52% of loss with the last five trading sessions.

Antares Pharma, Inc. (NASDAQ:ATRS) Worth an Investment?

Antares Pharma, Inc. (NASDAQ: ATRS) The 36 Months beta value for ATRS stocks is at 0.88, while 6 of the analysts out of 6 who provided ratings for Antares Pharma, Inc. stocks as a “buy” while 0 as overweight, 0 rated it as hold and 0 as sell. The average price we get from analysts is $5.98 which is $2.74 above current price. ATRS currently has a short float of 3.67% and public float of 149.28M with average trading volume of 1.08M shares.

ATRS Market Performance

ATRS stocks went down by -1.52% for the week, with the monthly jump of 9.09% and a quarterly performance of 13.29%, while its annual performance rate touched 1.25%. The simple moving average for the period of the last 20 days is 1.62% for ATRS stocks with the simple moving average of 3.84% for the last 200 days.

ATRS Stocks 3.81% Far from 50 Day Moving Average

After a stumble in the market that brought ATRS to its low price for the period of the last 52 weeks, Antares Pharma, Inc. was unable to take a rebound, for now settling with -18.18% of loss for the given period.

The stock volatility was left at 3.87%, however, within the period of a single month, the volatility rate increased by 3.41%, while the shares surge at the distance of +6.93% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +11.72% upper at the present time.

In the course of the last 5 trading sessions, ATRS went down by -1.52%, which changed the moving average for the period of 200 days to the total of +0.31% of gains for the stock in comparison to the 20-day moving average settled at $3.20. In addition, Antares Pharma, Inc. saw 19.12% in overturn over the period of a single year with a tendency to cut further gains.

ATRS Stock Insider Trading

Reports are indicating that there were more than several insider trading activities at Antares Pharma, Inc. (ATRS), starting from GARRITY THOMAS J, who sold 30,000 shares at the price of $2.67 back on May 01. After this action, Rushing now owns 160,213 shares of Antares Pharma, Inc., valued at $79,968 with the latest closing price.

JACOB LEONARD S, the Director of Antares Pharma, Inc., sold 92,078 shares at the value of $3.00 during a trade that took place back on Apr 08, which means that JACOB LEONARD S is holding 239,892 shares at the value of $276,243 based on the most recent closing price.

ATRS Stock Fundamentals

The current profitability levels are settled at -26.12 for the present operating margin and +50.18 for gross margin. The net margin for Antares Pharma, Inc. stands at -10.25. Total capital return value is set at -27.10, while invested capital returns managed to touch -10.90. Equity return holds the value -9.70%, with -3.80% for asset returns.

Based on Antares Pharma, Inc. (ATRS), the company’s capital structure generated 64.42 points for debt to equity in total, while total debt to capital is set at the value of 39.18. Total debt to assets is settled at the value of 28.46 with long-term debt to equity ratio rests at 56.62 and long-term debt to capital is 34.44.

The value for Enterprise to Sales is 6.00 with debt to enterprise value settled at 0.06. The receivables turnover for Antares Pharma, Inc. is 3.08 with the total asset turnover at the value of 0.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.62.